US 11,851,464 B2
Methods and compositions related to recombinant NEIL2
Tapas Hazra, Galveston, TX (US); Sanjiv Sur, Galveston, TX (US); and Ashok Chopra, Galveston, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Apr. 11, 2022, as Appl. No. 17/717,313.
Application 17/717,313 is a division of application No. 16/585,271, filed on Sep. 27, 2019, abandoned.
Claims priority of provisional application 62/738,605, filed on Sep. 28, 2018.
Prior Publication US 2022/0259274 A1, Aug. 18, 2022
Int. Cl. C07K 14/47 (2006.01); A61P 11/00 (2006.01); C12N 15/85 (2006.01); A61P 31/04 (2006.01)
CPC C07K 14/47 (2013.01) [A61P 11/00 (2018.01); A61P 31/04 (2018.01); C12N 15/85 (2013.01); C07K 2319/01 (2013.01); C12N 2015/8518 (2013.01)] 7 Claims
 
1. A method of treating bacterial infection or allergen induced rhinitis or allergen induced asthma comprising administering to a subject having a bacterial infection of the lungs or allergen induced rhinitis or allergen induced asthma a NEIL2 polypeptide comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1 non-covalently coupled to a lung targeting moiety,the lung targeting moiety localizing the NEIL2 polypeptide in the cytosol or nucleus of the targeted cell, wherein damage to transcribed genomic DNA in the lung is reduced relative to a subject not treated with said NEIL2 polypeptide, thereby ameliorating the negative effect of bacterial infection of the lung on an innate immune response in the subject.